Global Blood Collection Tubes for Liquid Biopsy Market Size By Type (Plastic, Glass), By Application (IVD, Research Use), By Region, And Segment Forecasts, 2023 to 2032

The Global Blood Collection Tubes for Liquid Biopsy Market was valued at USD 232.1 million in 2023 and is projected to reach USD 624.8 million by 2031, expanding at a CAGR of 13.1% during the forecast period from 2023 to 2031. The market is experiencing robust growth driven by the rising adoption of liquid biopsy techniques in oncology, increasing demand for minimally invasive diagnostic procedures, and growing awareness of early cancer detection. Blood collection tubes specifically designed for liquid biopsy play a crucial role in preserving cell-free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes, ensuring accurate downstream analysis.

Drivers:

1. Rising Prevalence of Cancer:

The global increase in cancer cases is driving demand for diagnostic solutions like liquid biopsy, which requires specialized blood collection tubes to ensure the integrity of biomarkers.

2. Increasing Adoption of Non-Invasive Diagnostic Methods:

Liquid biopsy offers a safer, faster, and more patient-friendly alternative to traditional tissue biopsy. This shift is fueling the demand for high-performance blood collection tubes that preserve nucleic acids and other analytes effectively.

3. Advancements in Genomic and Molecular Technologies:

The evolution of next-generation sequencing (NGS) and PCR-based diagnostic platforms is boosting the need for specialized collection tubes that ensure sample stability for precise genomic analysis.

Restraints:

1. High Cost of Specialized Tubes:

Premium pricing of blood collection tubes designed for liquid biopsy can limit widespread adoption, especially in low- and middle-income countries.

2. Regulatory and Standardization Challenges:

Variability in product standards and approval requirements across regions creates hurdles for global market penetration.

Opportunity:

1. Expansion into Emerging Markets:

Rising healthcare investments and cancer screening programs in Asia-Pacific and Latin America present lucrative opportunities for market players.

2. Development of Multi-Omics Tubes:

There is a growing interest in tubes that support collection for multi-omics applications—including genomics, proteomics, and metabolomics—which could open new revenue streams for manufacturers.

Market by System Type Insights:

Based on system type, the cfDNA blood collection tubes segment accounted for the largest share in 2023. These tubes are specifically designed to stabilize nucleic acids and are widely used in oncology research and clinical diagnostics. The segment is anticipated to maintain dominance throughout the forecast period due to their critical role in high-precision applications like liquid biopsy.

Market by End-Use Insights:

In terms of end use, the Clinical Laboratories segment held the largest revenue share in 2023. This is attributed to the widespread application of liquid biopsy testing in hospital-affiliated and independent laboratories. The Research Institutes segment is also expected to grow significantly, driven by ongoing clinical trials and cancer biomarker discovery efforts.

Market by Regional Insights:

North America led the global market in 2023 due to advanced healthcare infrastructure, early adoption of liquid biopsy techniques, and a high prevalence of cancer. However, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. Rising healthcare spending, increasing awareness, and improving diagnostic infrastructure in countries like China, India, and South Korea are major contributing factors.

Competitive Scenario:

Key players in the Global Blood Collection Tubes for Liquid Biopsy Market include Becton, Dickinson and Company, QIAGEN N.V., Roche Diagnostics, Streck, Inc., Bio-Rad Laboratories, Inc., Norgen Biotek Corp., Greiner Bio-One International GmbH, and Thermo Fisher Scientific, Inc. These companies are focusing on expanding their product portfolios, securing regulatory approvals, and forming strategic collaborations to strengthen their market position.

Scope of Work – Global Blood Collection Tubes for Liquid Biopsy Market

Report Metric Details

Market Size (2023) USD 232.1 million

Projected Market Size (2031) USD 624.8 million

CAGR (2023–2031) 13.1%

Market Segments By System Type, By End-Use, By Region

Growth Drivers Rising cancer incidence, shift to non-invasive diagnostics, NGS adoption

Opportunities Emerging markets, development of multi-omics tubes

Key Market Developments:

March 2024: QIAGEN launched a next-generation cfDNA blood collection tube with improved temperature stability, enhancing transportation and storage flexibility.

January 2024: Roche Diagnostics announced a collaboration with a leading cancer center in the U.S. to develop standardized liquid biopsy workflows using its collection tube portfolio.

August 2023: Streck, Inc. expanded its blood collection tube product line to include specialized tubes for both cfRNA and exosomal biomarker preservation.

FAQs:

1. What is the current market size of the Global Blood Collection Tubes for Liquid Biopsy Market?

The market size in 2023 is valued at USD 232.1 million.

2. What is the major growth driver of the Global Blood Collection Tubes for Liquid Biopsy Market?

The major driver is the increasing adoption of non-invasive cancer diagnostics through liquid biopsy.

3. Which is the largest region during the forecast period in the Global Blood Collection Tubes for Liquid Biopsy Market?

North America holds the largest market share, while Asia-Pacific is expected to grow fastest.

4. Which segment accounted for the largest market share in the Global Blood Collection Tubes for Liquid Biopsy Market?

The cfDNA blood collection tubes segment held the largest share in 2023.

5. Who are the key market players in the Global Blood Collection Tubes for Liquid Biopsy Market?

Key players include